Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 ...

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics.

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

In other developments, Regulus reported a net loss per share of ($0.20) for the fourth quarter, slightly better than the expected ($0.21), with a cash position of $75.8 million to fund operations ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus").

Novartis today announced that its previously announced tender offer (the "Offer") by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ...

In other recent news, Regulus Therapeutics has entered into an acquisition agreement with Novartis, with the transaction valued at approximately $1.7 billion. This deal includes an initial payment of ...